Objective -To assess whether physical growth is affected in early treated Dutch patients with phenylketonuria (PKU). Methods -The birth weights of all 137 early detected patients with PKU born in the period from 1974 to 1988 in the Netherlands were compared with reference values. Height, head circumference, and weight were measured at the age at which treatment started (commonly about 2-3 weeks), at 6 months of age, and yearly from the child's first birthday up to the age of 10 years. These measurements were compared with reference values. Results -The adjusted birth weight in patients with PKU was 141 g (95% confidence interval (CI) 66 to 216 g) less than Dutch reference values by Kloosterman and 103 g (95% CI 9 to 196 g) less compared with the birth weight ofanother reference group. At the age at which treatment started, z scores of patients for height by age were -0-23 (95% CI -0 44 to -0.02) and z scores for head circumference by age were -0 25 (95% CI -0 44 to -0.06). From the age at which treatment started up to the age of 3 years z scores for height by age further decreased to -0 74 (95% confidence interval -0 93 to -0.56), after which no additional decrease occurred. In contrast, z scores for head circumference increased from -0 25 at the first visit to 0-08 (95% CI -0-14 to 0.30) at the age of 1 year, after which they remained close to zero. Weight by height was close to the expected centiles for all ages. Conclusion -Patients with PKU are growth retarded at birth and have smaller head circumferences than the normal population. In Dutch patients further growth retardation occurs in the first three years of life.
age of 1 Only studies with a large number of patients have sufficient statistical power to detect these effects. To our knowledge the only longitudinal study that has provided information on the growth of a large number of patients with PKU is the American collaborative study of children treated for phenylketonuria. The results of this study have shown that in the period from birth to 10 years of age, children with PKU had almost identical height for age and head circumference for age (only followed up to 7 years of age), but were heavier than reference children.-8 A Swiss study also could not detect impairments in growth, but this study included only 20 patients with PKU.9 In contrast, Dutch patients with PKU have been found to be smaller than would be expected from national standards. 10 1 1 As these analyses were cross sectional, it is unclear whether they reflect a smaller stature before the start of treatment, growth failure after treatment, or a combination of the two. We therefore performed a longitudinal analysis to answer this question. 15 As the measurements were not performed at exactly the same ages in all children, height and head circumference were converted into z scores by subtracting the expected mean measurement for that age in days and sex, and dividing by its standard deviation. As weight by height is not normally distributed,14 we calculated the percentage of the patients that had a weight by height below the 10th centile and the percentage that had a weight by height above the 90th centile.
Patients and methods

Results
BIRTH WEIGHT
The mean birth weight of the 137 patients with PKU was 3271 g (SD 564 g). I- A decrease in birth weight in patients with PKU has also been reported by Saugstad.'6 He found that the mean birth weight in patients with PKU was 500 g less than that of healthy siblings. However, this finding could not be confirmed by two other studies in which patients with PKU were compared with their unaffected siblings.17 18 One of these studies found that patients with PKU weighed 51 g less,'7 whereas the other found that patients weighed 40 g less. 18 These differences were not statistically significant. As the number of patients with PKU in these studies was small Mean z s Impaired prenatal and postnatal growth in Dutch patients with phenylketonunia (40 and 56), the failure to find a statistically significant result could be due to low statistical power. These findings, combined with our results, suggest that patients with PKU are indeed growth retarded at birth, but that the size of the effect is likely to be smaller than reported by Saugstad.16 We previously reported a higher prevalence of congenital heart disease in patients with PKU. 19 We speculated that the slightly increased phenylalanine concentrations in the mothers of the patients may be the cause of the increased prevalence of congenital heart disease. These mothers are likely to be heterozygotes. Heterozygotes have increased phenylalanine concentrations compared with normal mothers, especially after protein intake and during pregnancy.20 21 In the offspring of mothers with extreme phenylalanine concentrations during pregnancy (as in maternal phenylketonuria) the prevalence of congenital heart disease, microcephaly, and low birth weight is much increased compared with the normal population. The measurements in our study were performed in eight different centres by a number of different people, and without centralised examination of the measuring instruments. This may increase the amount of random error and thereby decrease the precision of the results as well as the statistical power. As so many different people in many different settings performed the measurements, however, it is unlikely that there will be a systematic error (lack of validity) in the measurements.
We conclude that patients with PKU are growth retarded at birth and have smaller head circumferences than the normal population. In Dutch patients further growth retardation occurs in the first three years of life. 
Oral immunoglobulins for rotavirus gastroenteritis
Rotavirus infection causes some 900 000 deaths throughout the world each year and in the United States alone it is responsible for about one million cases of severe infantile diarrhoea and 150 deaths. Doctors in Italy have recently reported a prospective, placebo controlled, double blind trial of oral immunoglobulin in acute gastroenteritis (Alfredo Guarino and colleagues, Pediatrics 1994; 93: 12-6).
Ninety eight children aged between 2 and 36 months (mean 15 months) admitted to hospital in Naples were randomly assigned to receive either immunoglobulin (Sandoglobulin) 300 mg/kg body weight or 5% glucose by mouth. Three were excluded from the trial because they vomited back the fluid given. Of the remaining 95 children, 71 had rotavirus in their stools, 10 salmonella, and 14 no detected pathogens. In rotavirus gastroenteritis there was a highly significant reduction (p50.00001) in both duration of diarrhoea (76 v 131 hours) and duration of excretion of virus (113 v 179 hours) in the immunoglobulin treated group. Length of hospital stay was reduced from six to four days (p50-01). The immunoglobulin preparation used has specific neutralising activity against all four rotavirus strains tested. There was no significant benefit from immunoglobulin in salmonella enteritis or in those where no pathogens were found.
The only serious disadvantage of this treatment seems to be its cost (US$200 to treat a baby of 10 kg). Presumably this will restrict its use in those parts of the world where it might be most beneficial.
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